Methods of treating amyotrophic lateral sclerosis (ALS)
First Claim
Patent Images
1. A method of treating a subject with amyotrophic lateral sclerosis (ALS) comprising:
- a) isolating neural stem cells of human origin from a central nervous system tissue that comprises fetal spinal cord tissue;
b) expanding in vitro the isolated neural stem cells in a dispersed adherent culture to form an expanded population of neural stem cells, wherein expanding the isolated neural stem cells comprises;
i.) providing at least one extracellular protein to a culture vessel, wherein the extracellular protein includes at least about 10 μ
g/mL of poly-D-lysine and less than about 1 mg/ml fibronectin;
ii.) culturing the dissociated neural stem cells in said culture vessel in the absence of serum;
iii.) adding to the culture vessel at least one growth factor; and
iv.) passaging the cultured cells prior to confluence;
c) concentrating the expanded population of neural stem cells to a density of about 1,000 to about 200,000 cells/μ
L to form concentrated neural stem cells; and
d) injecting a therapeutically effective amount of said concentrated neural stem cells into one or more areas of a spinal cord of the subject.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention relates generally to methods of treating spasticity, rigidity, or muscular hyperactivity conditions by introducing a portion of an expanded population of neural stem cells into an area of a recipient spinal cord.
40 Citations
14 Claims
-
1. A method of treating a subject with amyotrophic lateral sclerosis (ALS) comprising:
-
a) isolating neural stem cells of human origin from a central nervous system tissue that comprises fetal spinal cord tissue; b) expanding in vitro the isolated neural stem cells in a dispersed adherent culture to form an expanded population of neural stem cells, wherein expanding the isolated neural stem cells comprises; i.) providing at least one extracellular protein to a culture vessel, wherein the extracellular protein includes at least about 10 μ
g/mL of poly-D-lysine and less than about 1 mg/ml fibronectin;ii.) culturing the dissociated neural stem cells in said culture vessel in the absence of serum; iii.) adding to the culture vessel at least one growth factor; and iv.) passaging the cultured cells prior to confluence; c) concentrating the expanded population of neural stem cells to a density of about 1,000 to about 200,000 cells/μ
L to form concentrated neural stem cells; andd) injecting a therapeutically effective amount of said concentrated neural stem cells into one or more areas of a spinal cord of the subject. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
Specification